ClinicalTrials.gg
CompletedNCT07506850Updated Apr 2, 2026

Effect of CPP-ACP Associated With NaF or SnF₂ on Post-Bleaching Tooth Sensitivity

An interventional study of CPP-ACPF and CPP-ACP+SnF2 in Tooth Sensitivity, sponsored by Universidade Federal do Para. Completed at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Universidade Federal do Para · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2025, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Dentin Sensitivity by Universidade Federal do Para — 2 open to participants now, 2 under way, 1 of them phase 3. Dentin Sensitivity · Universidade Federal do Para.

Enrollment
7th of 19
64 · median 50
Started
2025
with 1 other
No phase
14 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in Dentin Sensitivity by Universidade Federal do Para, this one is the 7th largest by enrollment, is one of 2 that started in 2025, is one of 14 with no phase, and was the 19th registered.

Dentin Sensitivity

292 studies on the registry are indexed under Dentin Sensitivity; 49 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

2 of the 19 studies in Dentin Sensitivity by Universidade Federal do Para are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 20 Dentin Sensitivity studies recruiting now, 6 (30%) set no upper age limit and 13 (65%) stop at 75 or younger; 2 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dentin Sensitivity by Universidade Federal do Para, or all of them as a file.
02

Study summary

This randomized, triple-blind, placebo-controlled clinical trial aims to evaluate the efficacy of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) associated with sodium fluoride (NaF) or stannous fluoride (SnF₂) in reducing tooth sensitivity following in-office dental bleaching.

Tooth bleaching with high-concentration hydrogen peroxide is widely used due to its effectiveness in improving dental aesthetics. However, tooth sensitivity remains the most common adverse effect associated with this procedure, negatively impacting patient comfort and satisfaction. Although several desensitizing strategies have been proposed, there is still no gold-standard protocol for managing post-bleaching sensitivity.

CPP-ACP is a remineralizing agent capable of releasing calcium and phosphate ions, promoting mineral deposition on the tooth surface and potentially occluding dentinal tubules. When combined with fluoride, its effects may be enhanced. Sodium fluoride (NaF) has been widely used in dentistry, while stannous fluoride (SnF₂) has gained attention due to its additional protective and anti-sensitivity properties. Recent evidence suggests that the combination of CPP-ACP and SnF₂ may enhance mineral uptake and improve protective effects on dental tissues.

A total of 66 participants will be randomly allocated into three groups (n=22): (1) CPP-ACP with NaF, (2) CPP-ACP with SnF₂, and (3) placebo control. All participants will undergo in-office bleaching with 35% hydrogen peroxide in two sessions, with a 7-day interval between sessions.

Desensitizing agents or placebo will be applied before and after each bleaching session. Tooth sensitivity will be assessed using a numeric rating scale (NRS) and a visual analog scale (VAS) at multiple time points up to 72 hours after each session. Color changes will be evaluated using a spectrophotometer based on the CIELAB system.

The study will test the hypothesis that CPP-ACP combined with fluoride agents reduces post-bleaching sensitivity without compromising whitening effectiveness. The findings may contribute to the development of more effective clinical protocols for managing bleaching-induced tooth sensitivity.

Read the detailed description

Tooth bleaching has become one of the most widely performed aesthetic dental procedures due to the increasing demand for whiter teeth and improved smile appearance. The procedure typically involves the use of hydrogen peroxide-based agents, which penetrate dental structures and release reactive oxygen species capable of oxidizing chromogenic molecules responsible for tooth discoloration.

Despite its effectiveness, in-office bleaching using high concentrations of hydrogen peroxide (≥35%) is frequently associated with tooth sensitivity, which is considered the most common adverse effect of the procedure. This sensitivity is believed to result from the diffusion of peroxide through enamel and dentin, reaching the pulp tissue and triggering an inflammatory response that activates nociceptors.

Various strategies have been proposed to minimize post-bleaching tooth sensitivity, including the use of desensitizing agents with neural or tubule-occluding mechanisms, anti-inflammatory drugs, and photobiomodulation therapy. However, no consensus has been established regarding the most effective approach.

Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) is a milk-derived complex with well-documented remineralizing properties. CPP stabilizes calcium and phosphate ions in an amorphous form, facilitating their release in the oral environment. These ions can be deposited on the tooth surface, forming a mineral reservoir that may help occlude dentinal tubules and reduce dentin permeability.

The addition of sodium fluoride (NaF) to CPP-ACP formulations enhances remineralization by promoting the formation of fluorapatite. Clinical studies suggest that CPP-ACP combined with NaF (CPP-ACPF) may reduce post-bleaching sensitivity by limiting the diffusion of reactive oxygen species and enhancing mineral deposition.

Stannous fluoride (SnF₂) has also been widely used in oral care products due to its anti-erosive, antimicrobial, and anti-sensitivity properties. Advances in formulation technology have improved the stability and bioavailability of Sn²⁺ ions, increasing its clinical effectiveness. Recent evidence indicates that combining SnF₂ with CPP-ACP may enhance the uptake of tin and fluoride ions into dental tissues, potentially improving protective and desensitizing effects.

However, there is limited clinical evidence evaluating the combined use of CPP-ACP and SnF₂ in the context of tooth bleaching. Therefore, this study aims to compare the effectiveness of CPP-ACP associated with NaF and CPP-ACP associated with SnF₂ in reducing tooth sensitivity after in-office bleaching, as well as to assess whether these interventions interfere with bleaching efficacy.

This study will be designed as a randomized, parallel-group, triple-blind, placebo-controlled clinical trial, conducted in accordance with CONSORT guidelines and ethical principles outlined in the Declaration of Helsinki. Participants will provide informed consent prior to enrollment.

A total of 66 participants, in good general and oral health, will be recruited. Eligible participants must present an upper right canine shade of A2 or darker according to the Vita Classical shade guide. Exclusion criteria include active caries, periodontal disease, restorations or prostheses in anterior teeth, visible cracks, severe intrinsic discoloration, dentin exposure, previous bleaching, orthodontic treatment, systemic conditions affecting oral health, pregnancy, lactation, and allergies to milk proteins or product components.

Participants will be randomly assigned into three groups (n=22 per group):

  1. CPP-ACP with sodium fluoride (MI Paste Plus),
  2. CPP-ACP with stannous fluoride (MI Paste ONE Perio),
  3. placebo control.

Randomization will be performed using computer-generated allocation, and allocation concealment will be ensured sealed opaque envelopes. The study will be triple-blinded, meaning that participants, operators, and outcome assessors will be unaware of group assignments. The desensitizing agents and placebo will be provided in identical containers.

All participants will undergo in-office bleaching using 35% hydrogen peroxide. Two bleaching sessions will be performed, with a 7-day interval. Each session will consist of three 15-minute applications, totaling 45 minutes.

The desensitizing agents or placebo will be applied before and after each bleaching session, following standardized procedures. Participants will be instructed to avoid eating or drinking for 30 minutes after application.

Tooth sensitivity will be assessed using two validated scales: a 5-point numeric rating scale (NRS) and a visual analog scale (VAS). Participants will record sensitivity at the following time points: during treatment, up to 1 hour, 1-24 hours, 24-48 hours, and 48-72 hours after each bleaching session.

Tooth color will be evaluated using a spectrophotometer (VITA Easyshade) based on the CIELAB color system (L*, a*, b*). Measurements will be taken at baseline, one week after the first session, one week after the second session, and 30 days after treatment. Color differences will be calculated using ΔE*ab and CIEDE2000 (ΔE00) formulas.

Data will be analyzed using appropriate statistical tests based on data distribution. Normality will be assessed using the Shapiro-Wilk test. Parametric or non-parametric tests will be applied accordingly, with a significance level of 5%.

The null hypotheses are that there will be no difference in tooth sensitivity among the groups and that the desensitizing protocols will not affect bleaching effectiveness. The results of this study may provide clinically relevant evidence for optimizing desensitizing protocols in in-office bleaching procedures, improving patient comfort without compromising aesthetic outcomes.

03

Conditions studied

  • Tooth Sensitivity

Browse trials for

Keywords

  • Tooth Sensitivity
  • Tooth Bleaching
  • Dentin Desensitizing Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older, of both sexes
  • Good general and oral health
  • Upper right canine classified as shade A2 or darker, according to the Vita Classical scale (VITA Zahnfabrik, Bad Säckingen, Germany)

Exclusion criteria

Exclusion Criteria:

  • Presence of active caries or periodontal disease
  • Visible cracks in upper or lower anterior teeth
  • Evident malocclusion
  • Restorations or prostheses in anterior teeth
  • Gastroesophageal disorders
  • Severe intrinsic tooth discoloration (e.g., tetracycline staining, fluorosis, or non-vital teeth)
  • Dentin exposure in anterior and/or posterior teeth
  • Parafunctional habits
  • Tooth sensitivity
  • Previous tooth bleaching or orthodontic treatment
  • Pregnant or lactating women
  • Individuals with allergies or sensitivities to milk protein or hydroxybenzoate-based preservatives
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Placebo comparator
    Control

    In this group, an experimental paste without an active ingredient was used, mimicking the color, texture, and flavor of the experimental pastes.

    Drug: Control (placebo)

  • Experimental
    CPP-ACPF

    n this group, an experimental paste of CPP-ACP combined with sodium fluoride.

    Drug: CPP-ACPF

  • Experimental
    CPP-ACP+SnF2

    In this group, an experimental paste of CPP-ACP combined with stannous fluoride

    Drug: CPP-ACP+SnF2

Interventions

  • DrugCPP-ACPF

    Apply MI Paste Plus to the buccal surface of the teeth for five minutes. During this time, the patient should keep their mouth closed and should not talk or move. This procedure was performed on arm 2.

  • DrugCPP-ACP+SnF2

    Drug page: Casein phosphopeptide-amorphous calcium phosphate nanocomplexStudies of Casein phosphopeptide-amorphous calcium phosphate nanocomplexCasein phosphopeptide-amorphous calcium phosphate nanocomplex pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apply MI Paste One Perio to the buccal surface of the teeth for five minutes. During this time, the patient should keep their mouth closed and should not talk or move. This procedure was performed on arm 3.

  • DrugControl (placebo)

    This intervention was performed on arm 1. A placebo paste was applied to the buccal surface of the teeth for five minutes. During this period, the patient had to keep their mouth closed and not speak or move.

06

What researchers measure

Primary outcomes

  1. Tooth Sensitivity

    Use Kruskal-Wallis ANOVA for within-group analysis and Friedman's test for within-group sensitivity data analysis.

    Time frame: "During bleaching", "1 hour after bleaching", "24 hours after bleaching", "48 hours after bleaching" and "72 hours after bleaching" in each whitening session.

07

Study locations

1 site
  • Universidade Federal do Pará
    Belém, Pará 66075-110, Brazil
08

References and documents

Publications

  • Bouya S, Balouchi A, Maleknejad A, Koochakzai M, AlKhasawneh E, Abdollahimohammad A. Cancer Pain Management Among Oncology Nurses: Knowledge, Attitude, Related Factors, and Clinical Recommendations: a Systematic Review. J Cancer Educ. 2019 Oct;34(5):839-846. doi: 10.1007/s13187-018-1433-6. PubMed 30315497 ↗
  • Chaves GC, Abi-Saab Arrieche M, Rode J, Mechali D, Reis PO, Alves RV, Stobbaerts E, Aguilar NG, Ribeiro I. [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America]. Rev Panam Salud Publica. 2017 Jun 8;41:e45. doi: 10.26633/RPSP.2017.45. Spanish. PubMed 28614468 ↗
  • Morsch P, Pereira GN, Navarro JH, Trevisan MD, Lopes DG, Bos AJ. [Clinical characteristics and social determinants in a sample of non-homebound elderly]. Cad Saude Publica. 2015 May;31(5):1025-34. doi: 10.1590/01021-311X00053014. Portuguese. PubMed 26083177 ↗
  • Kim YH, Boykin E, Stevens T, Lavrich K, Gilmour MI. Comparative lung toxicity of engineered nanomaterials utilizing in vitro, ex vivo and in vivo approaches. J Nanobiotechnology. 2014 Nov 26;12:47. doi: 10.1186/s12951-014-0047-3. PubMed 25424549 ↗
  • Oliveira Barros AP, da Silva Pompeu D, Takeuchi EV, de Melo Alencar C, Alves EB, Silva CM. Effect of 1.5% potassium oxalate on sensitivity control, color change, and quality of life after at-home tooth whitening: A randomized, placebo-controlled clinical trial. PLoS One. 2022 Nov 17;17(11):e0277346. doi: 10.1371/journal.pone.0277346. eCollection 2022. PubMed 36395262 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2025, 5 months.

Of 113 non-industry interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 5 months is below that.

Counting every sponsor, half of 147 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 2, 2026
StartActual
Feb 5, 2025
Primary completionActual
Jul 20, 2025
CompletionActual
Jan 29, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07506850
Lead sponsor
Universidade Federal do Para
Responsible party
Cecy Martins Silva (Professor Clínico, Universidade Federal do Para) — Principal investigator
First posted
Apr 2, 2026
Start date
Feb 5, 2025
Primary completion
Jul 20, 2025
Completion
Jan 29, 2026
Last update
Apr 2, 2026

Study contacts

Silva
principal investigator · Universiade Federal do Pará

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casein phosphopeptide-amorphous calcium phosphate nanocomplex

Start the discussion